Tumor-associated calcium signal transducer 2 (TACSTD2)

Where the papers sit

17 papers from the last 6 months study Tumor-associated calcium signal transducer 2 (TACSTD2) directly · updated from PubMed 5 Oct 2026

• TROP2 ADC Therapy

  TROP2-directed antibody-drug conjugates are moving from single-agent use toward better safety management, dynamic monitoring and combination therapy. Sacituzumab govitecan, sacituzumab tirumotecan and datopotamab deruxtecan recur across breast-cancer studies, especially pretreated and triple-negative disease. Pembrolizumab combinations and circulating-tumor-cell tracking seek to extend progression-free benefit and identify response. TROP2 expression and H-scores remain clinically relevant, but efficacy and tolerability across tumor types remain open questions.

  9 papers · 52.9%

• TROP2 in Lung Cancer

  TROP2-directed therapy is moving into advanced non-small-cell lung cancer, including sacituzumab tirumotecan with pembrolizumab. The work also targets drug-tolerant persister cells as a route to delay osimertinib and other EGFR tyrosine kinase inhibitor resistance. TROP2 expression is examined across conventional and transformed small-cell lung carcinomas, with MYC-associated transformation providing a recurring biological context. Whether ADCs can improve outcomes across EGFR-driven and small-cell-transformed disease remains unresolved.

  3 papers · 17.6%

• Others — Cancer Targeting and Biomarkers

  KRAS-MAPK inhibition is being linked to interferon signaling, cell-state transitions and new therapeutic vulnerabilities. TCR-JANUS engagers and tumor-targeted bispecifics aim to improve T-cell targeting across heterogeneous tumors while limiting toxicity. Proteomic studies instead pursue biomarker discovery, including extracellular-vesicle predictors of 177Lu-PSMA-617 outcomes. The cluster therefore spans immunotherapy, resistance biology and proteomics without a single shared direction.

  5 papers · 29.4%